StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) company profile

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

About Matinas BioPharma

Pharmaceutical Preparations, SIC 2834

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies utilizing its proprietary lipid nanocrystal delivery technology. The platform encapsulates small molecules and oligonucleotides to facilitate targeted, extrahepatic cellular delivery without toxicity, targeting applications in oncology and inflammation. The company's lead product candidate is MAT2203, an oral formulation of the potent antifungal agent amphotericin B engineered to treat life-threatening invasive fungal infections, including invasive aspergillosis, cryptococcal meningitis, and invasive candidiasis. The company develops these therapeutic candidates primarily for patients facing serious fungal infections who have limited or no alternative treatment options.

The company maintains its principal executive offices in Bedminster, New Jersey. Its clinical development activities have included approximately 65 planned clinical investigator sites across the United States. Following corporate restructuring, Matinas BioPharma actively seeks strategic partnerships to advance its late-stage clinical programs.

Summary of the business section of Matinas BioPharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Matinas BioPharma Holdings, Inc.
Headquarters
Bedminster, NJ
Address
1545 Route 206 South, Suite 302 07921
Phone
(908) 484-8805
Employees
2, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
EISNERAMPER LLP, Iselin, New Jersey

Stock & identifiers

Ticker
MTNB
Exchange
NYSE
IPO date
Jul 21, 2014
Shares outstanding
15M, Aug 10, 2026
Public float
$4.50M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-15 reverse, Sep 28, 2026; 1-for-50 reverse, Sep 3, 2024
SEC CIK
1582554
CUSIP
576810303
ISIN
US5768103039
FIGI
BBG005WX2XG8
Share class FIGI
BBG005WX2XH7
LEI
549300TGHXVKQ7EJRO41
EIN
46-3011414

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jerome D. JabbourPresident and CEO, Director810,011
An Evelyn DDirector–
Edward NeugeborenDirector–
Keith MurphyDirector–
Robin L. SmithDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024$598.00K$627.23K$586.92K$1–
FY2023$1.60M$843.21K$865.96K$21–
FY2022$1.67M$325.45K$859.64K$50–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusTotalvs. prior year
Jerome D. Jabbour
Chief Executive Officer
$598.00K–$598.00K-63%
James J. Ferguson
Former Chief Medical Officer
$468.00K$121.68K$589.68K-33%
Keith Kucinski
Chief Financial Officer
$416.00K$168.16K$584.16K-28%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of March 31, 2026, we had two full time employees and retained the services of two independent contractors/consultants.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?